natgillin/translations-raw huggingface dataset:
hepatitis (up to liver failure), raising of the white-cells count in the blood (leukocytosis, with or without eosinophilia) - reddening of the skin (erythema), rash in various types (e.g. itchy, with white spots, with blisters, with blisters containing pus, with shedding of the skin, measles-like rash), widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis (Stevens-Johnson Syndrome/Toxic epidermal necrolysis) - nervousness - feeling thirsty - ringing in the ears - blurred vision, change in vision - hair loss - mouth ulceration - inflammation of the pancreas: common symptoms are abdominal pain, nausea and vomiting - increased sweating - weight decrease, increased appetite, uncontrolled loss of appetite (anorexia) - muscle and/or joint stiffness - abnormally low blood cell counts (white or red blood cells or platelets) - urgent need to urinate - changes or decrease in urine amount due to inflammation in the kidneys (tubulointerstitial nephritis) - inflammation of the liver (hepatitis) - yellowing of the skin (jaundice) - liver damage - increased level of creatine phosphokinase in blood (an indicator of muscle damage) - sudden cardiac death. 
nekroza i odvajanje gornjeg sloja kože i sluznica sa stvaranjem mjehura, što rezultira ljuštenjem i mogućom sepsom (Stevens-Johnsonov sindrom/toksična epidermalna nekroliza) - nervoza - osjećaj žeđi - zvonjava u ušima - zamagljen vid, promjene vida - opadanje kose - ulceracije u ustima - upala gušterače: česti simptomi su bol u trbuhu, mučnina i povraćanje - pojačano znojenje - smanjenje tjelesne težine, pojačani apetit, nekontrolirani gubitak apetita (anoreksija) - ukočenost mišića i/ili zglobova - abnormalno nizak broj krvnih stanica (bijelih ili crvenih krvnih stanica ili krvnih pločica) - osjećaj hitnosti mokrenja - promjena ili smanjenje količine mokraće zbog upale bubrega (tubulointersticijski nefritis) - upala jetre (hepatitis) - žuta boja kože (žutica) - oštećenje jetre - povišena razina kreatin fosfokinaze u krvi (pokazatelj oštećenja mišića) - iznenadna srčana smrt.
A total of 1,086 patients were enrolled: febuxostat 80 mg QD (n=649), febuxostat 120 mg QD (n=292) and allopurinol 300/100 mg QD (n=145). 
Ukupno je bilo uključeno 1086 bolesnika: dobivali su febuksostat 80 mg jednom dnevno (n=649), febuksostat 120 mg jednom dnevno (n=292) i alopurinol 300/100 mg jednom dnevno (n=145).
Seven hundred sixty (760) patients were randomized: febuxostat 80 mg QD (n=256), febuxostat 120 mg QD (n=251), or allopurinol 300 mg QD (n=253). 
Sedamsto šezdeset (760) bolesnika je randomizirano te su primali: febuksostat 80 mg jednom dnevno (n=256), febuksostat 120 mg jednom dnevno (n=251), ili alopurinol 300 mg jednom dnevno (n=253).
For renally impaired subjects who were randomized to allopurinol, the dose was capped at 100 mg QD. 
U ispitanika s oštećenom funkcijom bubrega koji su randomizirani u skupinu liječenu alopurinolom, najviša doza bila je 100 mg jednom dnevno.
The recommended oral dose of Febuxostat Krka is 80 mg once daily without regard to food. 
Preporučena peroralna doza lijeka Febuxostat Krka je 80 mg jednom dnevno, neovisno o unosu hrane.
Dyspnoea, bronchitis, upper respiratory tract infection, cough 
Manje često Dispneja, bronhitis, infekcija gornjega dišnog sustava, kašalj
Febuxostat Krka works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. 
Krka djeluje dovoljno brzo da se ponovno mjerenje mokraćne kiseline u serumu može provesti nakon 2 tjedna.
Patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome treated with febuxostat should be under cardiac monitoring as clinically appropriate. 
Prevencija i liječenje hiperuricemije u bolesnika koji imaju rizik od nastajanja STL-a Bolesnicima liječenim febuksostatom koji su podvrgnuti kemoterapiji zbog hematoloških zloćudnih bolesti i imaju srednje visoki do visoki rizik od nastajanja sindroma tumorske lize treba pažljivo pratiti rad srca kako je klinički prikladno.
Febuxostat Krka 80 mg film-coated tablets Febuxostat Krka 120 mg film-coated tablets febuxostat 
Krka 80 mg filmom obložene tablete Febuxostat Krka 120 mg filmom obložene tablete febuksostat
Febuxostat Krka is available as either an 80 mg tablet or a 120 mg tablet. 
Dostupne su tablete lijeka Febuxostat Krka od 80 mg ili 120 mg.
Gout flares during the last 4 weeks of the study (Weeks 24-28) were observed in 15% (febuxostat 80, 120 mg), 14% (allopurinol 300 mg) and 20% (placebo) of subjects. 
Tijekom posljednja 4 tjedna ispitivanja (24.-28. tjedan) primijećeni su akutni napadi gihta u 15% (febuksostat 80 mg, 120 mg), 14% (alopurinol 300 mg) i 20% (placebo) ispitanika.
Two thousand and two hundred-sixty nine (2269) patients were randomized: febuxostat 40 mg QD (n=757), febuxostat 80 mg QD (n=756), or allopurinol 300/200 mg QD (n=756). 
Bilo je randomizirano 2269 bolesnika: febuksostat 40 mg jednom dnevno (n=757), febuksostat 80 mg jednom dnevno (n=756) ili alopurinol 300 mg/200 mg jednom dnevno (n=756).
Rare reports of serious allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock, have been collected in the post-marketing experience. 
Nakon stavljanja lijeka u promet su prikupljene rijetke prijave ozbiljnih alergijskih reakcija/reakcija preosjetljivosti, uključujući Stevens-Johnsonov sindrom, toksičnu epidermalnu nekrolizu i akutnu anafilaktičku reakciju/šok.
Febuxostat can be co-administered with naproxen with no dose adjustment of febuxostat or naproxen being necessary. 
Febuksostat se može primjenjivati istodobno s naproksenom, bez potrebe prilagodbe doze febuksostata ili naproksena.
Gout flares during the last 4 weeks of the study (Weeks 49-52) were observed in 6-8% (febuxostat 80 mg, 120 mg) and 11% (allopurinol 300 mg) of subjects. 
Tijekom posljednja 4 tjedna ispitivanja (49.-52. tjedan) primijećeni su akutni napadi gihta u 6 do 8% (febuksostat 80 mg, 120 mg) i 11% (alopurinol 300 mg) ispitanika.
If you stop taking Febuxostat Krka your uric acid levels may begin to rise and your symptoms may worsen due to the formation of new crystals of urate in and around your joints and kidneys. 
Ako prestanete uzimati Febuxostat Krka, razina mokraćne kiseline može početi rasti i simptomi
In the CONFIRMS study, the proportion of patients achieving the primary efficacy endpoint (sUA < 6.0 mg/dL at the final visit) for patients with a baseline serum urate level of ≥ 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD 49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively. 
Udio bolesnika koji su postigli primarni ishod djelotvornosti (razina mokraćne kiseline u serumu <6,0 mg/dl na završnoj kontroli) u CONFIRMS ispitivanju, a kojima je početna razina mokraćne kiseline u serumu bila ≥10 mg/dl bio je 27% (66/249) kod bolesnika liječenih febuksostatom od 40 mg jednom dnevno, 49% (125/254) kod liječenih febuksostatom od 80 mg jednom dnevno te 31% (72/230) kod bolesnika liječenih alopurinolom 300 mg/200 mg jednom dnevno.
Possible symptoms of allergic reactions might be: - rash including severe forms (e.g. blisters, nodules, itchy, exfoliative rash), itchiness - swelling of limbs or face - difficulties in breathing - fever with enlarged lymph nodes - but also serious life threatening allergic conditions with cardiac and circulatory arrest. 
svrbež - oticanje udova ili lica - poteškoće s disanjem - vrućica s povećanim limfnim čvorovima - ali i ozbiljna alergijska stanja opasna po život sa srčanim i cirkulatornim zastojem.
Febuxostat Krka is indicated in adults. 
Krka je indiciran u odraslih.
Febuxostat Krka 120 mg tablets febuxostat 
Krka 120 mg tablete febuksostat
Febuxostat Krka 80 mg tablets febuxostat 
Krka 80 mg tablete febuksostat
Over time, gout flares will occur less often and be less painful if you keep taking Febuxostat Krka every day. 
S vremenom će se, ako nastavite uzimati Febuxostat Krka svaki dan, napadaji gihta pojavljivati rjeđe i biti manje bolni.
In this subgroup febuxostat achieved the primary efficacy endpoint (sUA < 6.0 mg/dL at the last 3 visits) in 41% (80 mg QD), 48% (120 mg QD), and 66% (240 mg QD) of patients compared to 9% in the allopurinol 300 mg/100 mg QD and 0 % in the placebo groups. 
U ovoj podskupini febuksostat je postigao primarni ishod djelotvornosti (razina mokraćne kiseline u serumu <6,0 mg/dl prilikom zadnje 3 kontrole) u 41% (80 mg jednom dnevno), 48% (120 mg jednom dnevno) i 66% (240 mg jednom dnevno) bolesnika, u usporedbi s 9% u skupini koja je primala alopurinol 300 mg/100 mg jednom dnevno i 0% u skupini koja je primala placebo.
An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study, and showed that febuxostat was significantly more efficacious in lowering serum urate levels to < 6 mg/dL compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65% of patients studied). 
U CONFIRMS ispitivanju je prospektivno analizirana skupina bolesnika s gihtom i oštećenom funkcijom bubrega, te je pokazano da je u bolesnika s gihtom i blago do umjereno oštećenom funkcijom bubrega (65% promatranih ispitanika), febuksostat značajno djelotvorniji u sniženju razine serumskih urata na <6,0 mg/dl u odnosu na alopurinol 300 mg/200 mg.
Gout: The recommended dose in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment. 
Giht: preporučeno doziranje u bolesnika s blagim oštećenjem funkcije jetre je 80 mg.
No dose adjustment was required for enrolled patients on the basis of hepatic function. 
U ispitanika uključenih u ispitivanje nije bila potrebna prilagodba doze prema funkciji jetre.
In the post registrational CARES trial (see section 5.1 for detailed characteristics of the study) the rate of MACE events was similar in febuxostat versus allopurinol treated patients (HR 1.03;95% CI 0.871.23), but a higher rate of cardiovascular deaths was observed (4.3% vs. 3.2% of patients; HR 1.34; 95% CI 1.03-1.73). 
Major Adverse Cardiovascular Events, MACE) bila je slična u bolesnika liječenih febuksostatom i bolesnika liječenih alopurinolom (HR 1,03; 95% CI 0,87-1,23), ali je u bolesnika liječenih febuksostatom primijećena viša stopa kardiovaskularne smrti (4,3% u odnosu na 3,2% bolesnika; HR 1,34; 95% CI 1,03-1,73).
Iron oxide, yellow (E172) 
Ovojnica tablete poli(vinilni alkohol) makrogol 3350 titanijev dioksid (E171) talk željezov oksid, žuti (E172)
Table 1: Adverse reactions in combined phase 3, long-term extension studies and post-marketing experience 
Tablica 1: Nuspojave u fazi 3 dugoročnih produžetaka ispitivanja i nakon stavljanja lijeka u promet Poremećaji krvi i limfnog sustava Rijetko
Modelling and simulation analysis of data from a pre-clinical study in rats indicates that, in case of concomitant administration with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to 20% or less of the previously prescribed dose (see section 4.4 and 5.3). 
Analiza podataka iz modeliranja i simulacije u nekliničkom ispitivanju na štakorima ukazuje da je, u slučaju istodobne primjene s febuksostatom, dozu merkaptopurina/azatioprina potrebno smanjiti na 20% ili niže od prethodno propisane doze (vidjeti dijelove 4.4 i 5.3).
The reccomended oral dose of Febuxostat Krka is 120 mg once daily without regard to food. 
Sindrom tumorske lize: preporučena peroralna doza lijeka Febuxostat Krka je 120 mg jednom dnevno, neovisno o unosu hrane.
Febuxostat Krka 80 mg film-coated tablets febuxostat 
Krka 80 mg filmom obložene tablete febuksostat
Febuxostat Krka 120 mg film-coated tablets febuxostat 
Krka 120 mg filmom obložene tablete febuksostat
Febuxostat Krka contains lactose and sodium 
Krka sadrži laktozu i natrij
IJ 
Dob
Febuxostat Krka 120 mg film-coated tablets 
Krka 120 mg filmom obložene tablete
España KRKA Farmacéutica, S.L. 
KRKA Pharma Dublin, Ltd.
Febuxostat Krka 80 mg film-coated tablets 
Krka 80 mg filmom obložene tablete
Prevention and treatment of high uric acid levels in patients undergoing cancer chemotherapy Febuxostat Krka is available as a 120 mg tablet. 
Prevencija i liječenje visokih razina mokraćne kiseline kod bolesnika koji su podvrgnuti kemoterapiji za rak
Mean (±SEM) Serum Uric Acid Level (mg/dL) 
Primarni ishod u podskupini bolesnika s mokraćnom kiselinom u serumu ≥10 mg/dl
Renal failure, nephrolithiasis, haematuria, pollakiuria, proteinuria 
Zatajenje bubrega, nefrolitijaza, hematurija, polakizurija, proteinurija
Gout flares 
Napadi gihta
Tablet core 
Peroralna primjena.
Following an 80 mg oral dose of 
Nakon peroralno primijenjene doze od 80 mg febuksostata označenog s
Febuxostat Krka works by reducing uric acid levels. 
Krka djeluje tako da smanjuje razinu mokraćne kiseline.
Iron oxide, red (E172) 
Ovojnica tablete poli(vinilni alkohol) makrogol 3350 titanijev dioksid (E171) talk željezov oksid, crveni (E172)
KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 658 
KRKA - FARMA d.o.o. Tel: + 385 1 6312 100
The recommended dose in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment. 
Preporučeno doziranje u bolesnika s blagim oštećenjem funkcije jetre je 80 mg.
Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, Marketing Authorisation Holders in the Member States 
Popis naziva, farmaceutskih oblika, jačina lijeka, puteva primjene, nositelja odobrenja u državama članicama
2719 EE Zoetermeer The Netherlands cream; hydrophilic cutaneous use 
Louis Pasteurlaan 5 2719 EE Zoetermeer The Netherlands krema; hidrofilna
EMLA 5% w/w Cream lidocaine prilocaine 
EMLA 5% w/w Cream lidokain prilokain
Emla krém 5% lidocaine prilocaine 
Emla krém 5% lidokain prilokain
Emla Cream 5% lidocaine prilocaine 
Emla Cream 5% lidokain prilokain
This summary was last updated in 10-2017. 
Sažetak je posljednji put ažuriran: 10.2017.
In addition, 81% of these bleeding episodes required only a single treatment with Advate. 
Osim toga, 81 % tih epizoda krvarenja zahtijevalo je samo jedan tretman lijekom Advate.
Hypersensitivity (allergic) reactions have been reported and may in some cases become severe. 
Zabilježene su reakcije preosjetljivosti (alergijske reakcije) koje u nekim slučajevima mogu postati ozbiljne.
The full EPAR for Advate can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjelovito europsko javno izvješće o procjeni (EPAR) lijeka Advate nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Advate octocog alfa 
Advate oktokog alfa
Other information about Advate 
Ostale informacije o lijeku Advate
The European Commission granted a marketing authorisation valid throughout the EU for Advate on 2 March 2004. 
Europska komisija izdala je odobrenje za stavljanje lijeka Advate u promet koje vrijedi na prostoru Europske unije od 2. ožujka 2004.
Octocog alfa is made by a method known as ‘recombinant DNA technology': it is made by cells into which a gene (DNA) has been introduced that makes them able to produce it. 
Oktokog alfa proizvodi se metodom poznatom pod nazivom „tehnologija rekombinantne DNK”: tvori se od stanica u koje je uveden gen (DNK) koji im omogućuje da ga proizvode.
The additional studies confirmed Advate's effectiveness, including in children under 6 years of age. 
Dodatnim ispitivanjima potvrđena je djelotvornost lijeka Advate i u djece mlađe od 6 godina.
Advate is similar to another medicine approved in the EU called Recombinate, but it is prepared differently so that there are no human- or animal-derived proteins in the medicine. 
Lijek Advate sličan je drugom lijeku odobrenom u EU-u pod nazivom Recombinate, ali se proizvodi na drugačiji način, tako da u njemu ne postoje proteini ljudskog ili životinjskog podrijetla.
Advate is intended for either short-term or long-term use. 
Lijek Advate predviđen je za kratkotrajnu ili dugotrajnu primjenu.
What measures are being taken to ensure the safe and effective use of Advate? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Advate?
This is a summary of the European public assessment report (EPAR) for Advate. 
Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Advate.
What is Advate and what is it used for? 
Što je Advate i za što se koristi?
Common side effects with Advate (affecting between 1 and 10 patients in 100) are headache and pyrexia (fever). 
Česte nuspojave lijeka Advate (javljaju se u 1 do 10 na 100 bolesnika) jesu glavobolja i pireksija (vrućica).
What are the risks associated with Advate? 
Koji su rizici povezani s lijekom Advate?
Three additional studies looked at the use of the medicine in the prevention of bleeding and in surgery in patients with severe or moderately severe haemophilia A, including one study in 53 children under the age of 6 years. 
U tri dodatna ispitivanja proučavana je uporaba lijeka u sprečavanju krvarenja i tijekom kirurškog zahvata u bolesnika s teškom ili umjereno teškom hemofilijom A, uključujući ispitivanje na 53 djece mlađe od 6 godina.
Why is Advate approved? 
Zašto je lijek Advate odobren?
It is not intended to provide practical advice on how to use Advate. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Advate.
The dose and duration of treatment depend on whether Advate is used to treat or prevent bleeding or during surgery, as well as on the patient's factor VIII levels, the seriousness of the haemophilia, the extent and location of the bleeding and the patient's condition and bodyweight. 
Doza i trajanje liječenja ovise o tome primjenjuje li se lijek Advate za liječenje ili sprečavanje krvarenja ili tijekom kirurškog zahvata, kao i o razinama faktora VIII u bolesnika, o stupnju hemofilije, jačini i mjestu krvarenja te stanju i tjelesnoj težini bolesnika.
The data provided on immune tolerance induction in patients with inhibitors were not considered sufficient to specifically approve the medicine for this use. 
Podatci o induciranoj imunotoleranciji u bolesnika s inhibitorima smatrani su nedostatnima kako bi se lijek odobrio posebno za tu primjenu.
The study went on to look at the number of bleeding episodes and rated Advate's effectiveness in stopping bleeding on a scale from ‘none' to ‘excellent' in 107 patients, all of whom received Advate. 
Ispitivanjem se razmatrao broj epizoda krvarenja te je djelotvornost lijeka Advate u zaustavljanju krvarenja ocijenjena na ljestvici od „nikakva” do „izvrsna” u 107 bolesnika koji su svi primali lijek Advate.
It contains the active substance octocog alfa (human coagulation factor VIII). 
Lijek sadržava djelatnu tvar oktokog alfa (ljudski koagulacijski faktor VIII).
Advate must not be used in people who are hypersensitive (allergic) to human coagulation factor VIII, to mouse or hamster protein, or to any of the other ingredients. 
Lijek Advate ne smije se primjenjivati u osoba koje su preosjetljive (alergične) na ljudski koagulacijski faktor VIII, protein miša ili hrčka ili bilo koji drugi sastojak lijeka.
The Agency decided that Advate's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Agencija je zaključila da koristi lijeka Advate nadmašuju s njim povezane rizike te je preporučila davanje odobrenja za stavljanje lijeka u promet.
The Agency concluded that Advate has been shown to be effective at treating and preventing bleeding in patients with haemophilia A and has an acceptable safety profile. 
Agencija je zaključila da se lijek Advate pokazao djelotvornim u liječenju i sprečavanju krvarenja u bolesnika s hemofilijom A i da ima prihvatljiv sigurnosni profil.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Advate have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Advate nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
For more information about treatment with Advate, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o liječenju lijekom Advate pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
Advate is a medicine used for the treatment and prevention of bleeding in patients of all ages with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII). 
Advate je lijek koji se koristi za liječenje i sprečavanje krvarenja u bolesnika svih dobi s hemofilijom A (nasljednim poremećajem krvarenja uzrokovanim manjkom faktora VIII).
Advate can only be obtained with a prescription and treatment should be started by a doctor experienced in the treatment of haemophilia and with resuscitation equipment available in case of severe allergic reaction (anaphylaxis). 
Lijek Advate izdaje se samo na recept, a liječenje mora započeti liječnik s iskustvom u liječenju hemofilije i opremom za reanimaciju dostupnom u slučaju teške alergijske reakcije (anafilaksa).
How is Advate used? 
Kako se Advate koristi?
Advate is available as a powder and solvent that are mixed together to make a solution for injection into a vein. 
Lijek Advate dostupan je u obliku praška i otapala koji se miješaju kako bi se pripremila otopina za intravensku injekciju.
The active substance in Advate, octocog alfa (human coagulation factor VIII), is a substance that helps the blood to clot. 
Djelatna tvar u lijeku Advate, oktokog alfa (ljudski koagulacijski faktor VIII), tvar je koja pomaže u zgrušavanju krvi.
For practical information about using Advate, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o primjeni lijeka Advate bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svojem liječniku ili ljekarniku.
Advate given at high dose has been studied to see whether it is effective in clearing antibodies against factor VIII from the blood (a process known as immune tolerance induction) so that treatment with factor VIII remains effective. 
Ispitana je primjena velike doze lijeka Advate kako bi se utvrdilo je li on djelotvoran u uklanjanju protutijela za faktor VIII iz krvi (postupak poznat kao liječenje metodom inducirane imunotolerancije) tako da liječenje faktorom VIII ostane djelotvorno.
Advate is used to correct the factor VIII deficiency by replacing the missing factor VIII, giving temporary control of the bleeding disorder. 
Lijekom Advate nadomješćuje se nedostatak faktora VIII tako što se njime zamjenjuje faktor VIII koji nedostaje, čime se omogućuje privremena kontrola poremećaja krvarenja.
Some patients may develop factor VIII inhibitors, which are antibodies (proteins) that the body's immune system produces against factor VIII and which can cause the medicine to stop working resulting in a loss of bleeding control. 
Neki bolesnici mogu razviti inhibitore faktora VIII, odnosno protutijela (proteine) koje imunosni sustav proizvodi kako bi obranio organizam od faktora VIII, a koji mogu onemogućiti djelovanje lijeka i dovesti do gubitka kontrole nad krvarenjem.
For the full list of all side effects reported with Advate, see the package leaflet. 
Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Advate potražite u uputi o lijeku.
What benefits of Advate have been shown in studies? 
Koje su koristi lijeka Advate utvrđene u ispitivanjima?
Patients or their carers may be able to administer Advate themselves at home once they have been trained appropriately. 
Nakon odgovarajuće obuke, bolesnici ili njihovi njegovatelji mogu samostalno primjenjivati lijek Advate kod kuće.
The effectiveness of Advate was rated as ‘excellent' or ‘good' in 86% of 510 new bleeding episodes. 
U 86 % od 510 novih epizoda krvarenja djelotvornost lijeka Advate ocijenjena je kao „izvrsna” ili „dobra”.